Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today highlighted data presented at the American Association ...

Scientists at Memorial Sloan Kettering Cancer Center (MSK) and their colleagues are shedding new light on a tumor's earliest ...

ATCC and the Broad Institute of MIT and Harvard today announced new research describing the development of engineered ...

SEOUL, South Korea, April 17, 2026 /PRNewswire/ -- Penetrium Bioscience (KOSDAQ 187660) today announced compelling new scientific evidence demonstrating, for the first time at the cellular level, the ...

New data from Phase 2a clinical trial evaluating atebimetinib + mGnP in first-line pancreatic cancer will be presented in an oral session by Dr. Peter Vu, UC San Diego Health - ...

Fred Hutch Cancer Center molecular biologist Dr. Kevin Barry just received a $270,000, two-year grant from the American ...

Percheron Therapeutics Ltd (ASX:PER, OTC:PERCF) has presented new phase I clinical data for its cancer therapy candidate HMBD ...

Penetrium Bioscience (KOSDAQ 187660) today announced compelling new scientific evidence demonstrating, for the first time at ...

We need investment in precision medicine technologies to start programming cancer against itself, writes Cyriac Roeding.

New research finds a new strategy for treating a deadly cancer by combining existing drugs to indirectly weaken tumor growth, with potential implications for other cancers.

SP16 is an investigational intravenous therapy designed to treat chemotherapy-induced pain and peripheral neuropathy, also ...

Delve into the field of PARP inhibitors, a class that has gained traction in ovarian, breast, and prostate cancers.